Details of Disease

General Information of Disease (ID: DIS1OB2G)

• Disease Name: Head and neck neoplasm
• Synonyms: craniocervical region neoplasm (disease); craniocervical region neoplasm; head and neck neoplasm (excluding central nervous system); head and neck tumour; craniocervical region tumor; tumor of head and neck; tumor of craniocervical region; neoplasm of the head and neck; tumor of the head and neck; neoplasm of head and neck; tumour of craniocervical region; head and neck neoplasm; craniocervical region tumour; tumour of the head and neck; tumour of head and neck; neoplasm of craniocervical region; head and neck tumor
• Definition: A benign or malignant neoplasm that affects the anatomic structures of the head and neck region. Representative examples of benign neoplasms include salivary gland pleomorphic adenoma and nasal cavity papilloma. Representative examples of malignant neoplasms include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.
• Disease Hierarchy:
  DISTBY9Z: Tumour
  DIS1OB2G: Head and neck neoplasm
• Disease Identifiers:
  MONDO ID: MONDO_0005586
  MESH ID: D006258
  UMLS CUI: C0018671
  MedGen ID: 6728
  HPO ID: HP:0012288
  SNOMED CT ID: 255055008

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 27 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
RRM2	TT1S4LJ	Limited	Altered Expression	[1]
AREG	TT76B3W	moderate	Biomarker	[2]
BAP1	TT47RXJ	moderate	Biomarker	[3]
CEBPA	TT5LWG1	moderate	Biomarker	[4]
CSF3	TT5TQ2W	moderate	Therapeutic	[5]
DPYD	TTZPS91	moderate	Biomarker	[6]
FAT1	TTGUJYV	moderate	Biomarker	[7]
GPX1	TTYAHBP	moderate	Biomarker	[8]
MAPK1	TT4TQBX	moderate	Biomarker	[2]
MAPK3	TT1MG9E	moderate	Biomarker	[2]
TGFA	TTTLQFR	moderate	Biomarker	[2]
TYMS	TTP1UKZ	moderate	Biomarker	[6]
ADH7	TT3LE7P	Strong	Genetic Variation	[9]
BCL2L1	TTRE6AX	Strong	Biomarker	[10]
CD4	TTN2JFW	Strong	Biomarker	[11]
DSG3	TTEO4P8	Strong	Altered Expression	[12]
EPHB3	TT5LM7U	Strong	Biomarker	[13]
ERBB3	TTSINU2	Strong	Altered Expression	[14]
FGFR2	TTGJVQM	Strong	Genetic Variation	[15]
FURIN	TTH9WF6	Strong	Altered Expression	[16]
GJB6	TTAU8SJ	Strong	Altered Expression	[17]
PRAME	TTPH7T0	Strong	Biomarker	[18]
RAD51	TTC0G1L	Strong	Biomarker	[19]
RARB	TTISP28	Strong	Biomarker	[20]
STAT6	TTWOE1T	Strong	Biomarker	[21]
TMEM97	TT9NXW4	Strong	Biomarker	[22]
TP53	TT12KOD	Strong	Genetic Variation	[23]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC10	DTPS120	Strong	Altered Expression	[24]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ADH1B	DEEN9RD	Strong	Genetic Variation	[9]

This Disease Is Related to 16 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
APOBEC3B	OTHLNI51	Limited	Biomarker	[25]
GRP	OT8JDFNI	moderate	Biomarker	[2]
MAL	OTBM30SW	moderate	Biomarker	[26]
CYCS	OTBFALJD	Strong	Biomarker	[27]
DLGAP1	OTF2PUUI	Strong	Altered Expression	[28]
HELQ	OTL1STJT	Strong	Genetic Variation	[9]
HLCS	OTPDUX30	Strong	Biomarker	[27]
ICAM5	OTDGGAFH	Strong	Altered Expression	[29]
IFITM1	OTECO1G8	Strong	Biomarker	[30]
ING3	OTDIJXFP	Strong	Altered Expression	[31]
MAPK6	OTDDNF3Q	Strong	Altered Expression	[32]
MRPL11	OTLZ85U0	Strong	Biomarker	[33]
NAA25	OTS3QVF1	Strong	Genetic Variation	[9]
RAD17	OT1I93DT	Strong	Biomarker	[34]
S100A2	OTTGHJ1H	Strong	Altered Expression	[35]
SDHC	OTC8G2MX	Strong	Biomarker	[36]

References

• [1] RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.Clin Cancer Res. 2013 Jul 1;19(13):3416-28. doi: 10.1158/1078-0432.CCR-13-0073. Epub 2013 May 29.
• [2] SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.Cancer Res. 2004 Sep 1;64(17):6166-73. doi: 10.1158/0008-5472.CAN-04-0504.
• [3] Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.Genes Chromosomes Cancer. 2015 Jan;54(1):51-62. doi: 10.1002/gcc.22218. Epub 2014 Sep 18.
• [4] Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma.Cancer Res. 2007 May 15;67(10):4657-64. doi: 10.1158/0008-5472.CAN-06-4793.
• [5] Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.J Clin Oncol. 1993 Oct;11(10):2010-20. doi: 10.1200/JCO.1993.11.10.2010.
• [6] Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.Int J Mol Med. 2008 Dec;22(6):709-16.
• [7] Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation.Nat Genet. 2013 Mar;45(3):253-61. doi: 10.1038/ng.2538. Epub 2013 Jan 27.
• [8] Allelic loss at the GPx-1 locus in cancer of the head and neck.Biol Trace Elem Res. 2004 Nov;101(2):97-106. doi: 10.1385/BTER:101:2:097.
• [9] A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium.PLoS Genet. 2011 Mar;7(3):e1001333. doi: 10.1371/journal.pgen.1001333. Epub 2011 Mar 17.
• [10] Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.Mol Cancer Ther. 2008 Jun;7(6):1647-55. doi: 10.1158/1535-7163.MCT-07-2444.
• [11] Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer.Br J Cancer. 2005 Mar 14;92(5):913-20. doi: 10.1038/sj.bjc.6602407.
• [12] DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis.Oncogene. 2007 Jan 18;26(3):467-76. doi: 10.1038/sj.onc.1209802. Epub 2006 Jul 31.
• [13] Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.Mol Cancer Ther. 2018 Sep;17(9):2049-2059. doi: 10.1158/1535-7163.MCT-17-1163. Epub 2018 Jul 3.
• [14] erbB-3, a third member of the erbB/epidermal growth factor receptor gene family: its expression in head and neck cancer cell lines.Eur Arch Otorhinolaryngol. 1993;250(7):392-5. doi: 10.1007/BF00180383.
• [15] Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.Cancer Res. 2013 Aug 15;73(16):5195-205. doi: 10.1158/0008-5472.CAN-12-3950. Epub 2013 Jun 20.
• [16] Increased furin activity enhances the malignant phenotype of human head and neck cancer cells.Am J Pathol. 2003 Feb;162(2):439-47. doi: 10.1016/S0002-9440(10)63838-2.
• [17] Decreased expression of connexin-30 and aberrant expression of connexin-26 in human head and neck cancer.Anticancer Res. 2007 Jul-Aug;27(4B):2189-95.
• [18] The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005 Sep 23;122(6):835-47. doi: 10.1016/j.cell.2005.07.003.
• [19] Genetic variability of Xrcc3 and Rad51 modulates the risk of head and neck cancer.Gene. 2012 Aug 10;504(2):166-74. doi: 10.1016/j.gene.2012.05.030. Epub 2012 May 18.
• [20] RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age.Oncol Rep. 2007 Jul;18(1):105-12.
• [21] Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011 Aug;121(8):3100-8. doi: 10.1172/JCI43656. Epub 2011 Jul 18.
• [22] Triple-responsive expansile nanogel for tumor and mitochondria targeted photosensitizer delivery.Biomaterials. 2014 Nov;35(35):9546-53. doi: 10.1016/j.biomaterials.2014.08.004. Epub 2014 Aug 22.
• [23] Prospective enterprise-level molecular genotyping of a cohort of cancer patients.J Mol Diagn. 2014 Nov;16(6):660-72. doi: 10.1016/j.jmoldx.2014.06.004. Epub 2014 Aug 23.
• [24] Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines.Int J Oncol. 2007 Feb;30(2):393-401.
• [25] Evidence for APOBEC3B mutagenesis in multiple human cancers.Nat Genet. 2013 Sep;45(9):977-83. doi: 10.1038/ng.2701. Epub 2013 Jul 14.
• [26] T-lymphocyte maturation-associated protein gene as a candidate metastasis suppressor for head and neck squamous cell carcinomas.Cancer Sci. 2009 May;100(5):873-80. doi: 10.1111/j.1349-7006.2009.01132.x.
• [27] High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.Methods Mol Biol. 2018;1683:229-244. doi: 10.1007/978-1-4939-7357-6_14.
• [28] HOTAIRM1 competed endogenously with miR-148a to regulate DLGAP1 in head and neck tumor cells.Cancer Med. 2018 Jul;7(7):3143-3156. doi: 10.1002/cam4.1523. Epub 2018 Jun 14.
• [29] ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion!.Oral Oncol. 2005 Jul;41(6):580-8. doi: 10.1016/j.oraloncology.2005.01.002. Epub 2005 Apr 9.
• [30] Combination of IFITM1 knockdown and radiotherapy inhibits the growth of oral cancer.Cancer Sci. 2018 Oct;109(10):3115-3128. doi: 10.1111/cas.13640. Epub 2018 Sep 21.
• [31] Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer.Cancer Sci. 2008 Mar;99(3):531-8. doi: 10.1111/j.1349-7006.2007.00708.x. Epub 2007 Dec 15.
• [32] A regulatory BMI1/let-7i/ERK3 pathway controls the motility of head and neck cancer cells.Mol Oncol. 2017 Feb;11(2):194-207. doi: 10.1002/1878-0261.12021. Epub 2017 Jan 12.
• [33] Impaired mitochondrial protein synthesis in head and neck squamous cell carcinoma.Mitochondrion. 2015 Sep;24:113-21. doi: 10.1016/j.mito.2015.07.123. Epub 2015 Aug 1.
• [34] Downregulation of RAD17 in head and neck cancer.Head Neck. 2008 Jan;30(1):35-42. doi: 10.1002/hed.20660.
• [35] Down-regulation of S100A2 in lymph node metastases of head and neck cancer.Head Neck. 2007 Mar;29(3):236-43. doi: 10.1002/hed.20511.
• [36] Rationalization of genetic testing in patients with apparently sporadic pheochromocytoma/paraganglioma.Horm Metab Res. 2009 Sep;41(9):672-5. doi: 10.1055/s-0029-1202814. Epub 2009 Apr 2.